You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Moxifloxacin Therapy as a Risk Factor for Clostridium difficile–Associated Disease During an Outbreak: Attempts to Control a New Epidemic Strain
Priscilla Biller , MT(ASCP), CIC, Beth Shank , RN, BS, CIC, Leah Lind , MPH, Meghan Brennan , MD, Lisa Tkatch , MD, George Killgore , DrPH, Angela Thompson , MMSc and L. Clifford McDonald , MD
Infection Control and Hospital Epidemiology
Vol. 28, No. 2 (February 2007), pp. 198-201
Published by: Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Stable URL: http://www.jstor.org/stable/10.1086/511789
Page Count: 4
Preview not available
An outbreak of Clostridium difficile–associated disease (CDAD) caused by the epidemic North American pulsed‐field gel electrophoresis type 1 (NAP1) strain began after a formulary change from levofloxacin to moxifloxacin. Cases of CDAD were associated with moxifloxacin use, but a formulary change back to levofloxacin failed to reduce rates of disease. Substituting use of one fluoroquinolone with use of another without also controlling the overall use of drugs from this class is unlikely to control outbreaks caused by the NAP1 strain of C. difficile.
© 2007 by The Society for Healthcare Epidemiology of America. All rights reserved.